Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Qlucore, Nebion Collaborate

Published: Friday, February 07, 2014
Last Updated: Friday, February 07, 2014
Bookmark and Share
Partnership aims to address complementary use cases.

The start of 2014 will see Qlucore and Nebion AG working together to promote their two products Qlucore Omics Explorer and Genevestigator. 

Qlucore Omics Explorer is a next-generation bioinformatics software program which is extremely fast and allows the user to explore and analyse high-dimensional data sets interactively and in real time. Qlucore Omics Explorer has proved to be hugely beneficial to researchers in the life science and biotech industries when it comes to analysing big data.

Nebion creates innovative systems to extract high value information from the world's genomic data for biotechnology and personalized medicine. Its Genevestigator is a high-performance Web platform which deeply integrates expression data and curated sample annotations. This allows systematic screening of the database for genes that have unique expression properties and validation of target and biomarker genes by checking how they respond to thousands of experimental conditions.

"Nebion complements the Qlucore product offering perfectly by enabling a web based systematic screening of genes across many thousand experiments, so it makes perfect sense to work together to provide a broader solution to our clients. We're excited to be jointly promoting our complementary solutions to help researchers get better results, quickly," says Carl-Johan Ivarsson, CEO Qlucore.

Speaking on the new relationship between the two companies, Dr Philip Zimmermann, CEO Nebion commented, "I got to know Qlucore Omics Explorer a few years ago and I have become convinced that it's one of the best tools to find patterns in data and for biomarker discovery. It is very user-friendly but at the same time statistically robust."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Research Aims to Stop ‘Blood Doping' During Cycling and Other Competitive Sports
As cyclists take to the roads of Surrey, England, the subject of blood doping raises its head once again.
Thursday, August 01, 2013
Visualising Complex Data Results from 100,000 Cancer Patients
For decades, biomedical scientists have tried to develop a diagnostic tool for the early stages of cancer.
Wednesday, December 12, 2012
New Biomarkers Could Offer Vital Clues for Cancer Research
European funding for cancer research has led to some interesting results in recent years, says Carl-Johan Ivarsson, CEO at Qlucore.
Friday, May 04, 2012
New Research Techniques Could Help to Eliminate the Need for Animal Testing
Carl-Johan Ivarsson, Qlucore, comments on the reducing necessity for animal models in today’s drug development industry, as research moves more towards in vitro analysis.
Monday, March 19, 2012
Scientific News
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!